Vemurafenib: B-raf kinase inhibitor, oncolytic

Drugs of the Future

Volumn 36, Issue 3, 2011, Pages 191-199

  Puzanov, I ^a   Flaherty, K T ^b   Sosman, J A ^a   Grippo, J F ^c   Su, F ^c   Nolop, K ^d   Lee, R J ^c   Bollag, G ^d  

^a VANDERBILT INGRAM CANCER CENTER   (United States)

^b HARVARD UNIVERSITY   (United States)

^c HOFFMANN LA ROCHE INC   (United States)

^d PLEXXIKON INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE INHIBITOR; RO 5185426; UNCLASSIFIED DRUG; VEMURAFENIB;

ANTINEOPLASTIC ACTIVITY; ARTHRALGIA; DRUG DOSE ESCALATION; DRUG METABOLISM; DRUG SAFETY; DRUG SYNTHESIS; DRUG WITHDRAWAL; FATIGUE; HAND FOOT SYNDROME; HUMAN; MELANOMA; NAUSEA; NONHUMAN; PHOTOSENSITIVITY; PRURITUS; RASH; REVIEW; SQUAMOUS CELL CARCINOMA; WEIGHT REDUCTION;

EID: 84952979655     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2011.036.03.1590788     Document Type: Review

References (37)

1. Ibrahim, P.N., Artis, D.R., Bremer, R. et al. (Plexxicon, Inc.). Pyrrolo[2,3- b]pyridine derivatives as protein kinase inhibitors. JP 20008546797, WO 2007002325.
2. Ibrahim, P.N., Artis, D.R., Bremer, R. et al. (Plexxicon, Inc.). Pyrrolo[2,3-b]pyridine derivatives as protein kinase inhibitors. EP 1893612, WO 200700233.
3. Sebolt-Leopold, J.S., Herrera, R. Targeting the mitogen-activated protein kinase cascade to treat cancer. Nat Rev Cancer 2004, 4(12): 937-47.
4. McCubrey, J.A., Steelman, L.S., Chappell, W.H. et al. Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim Biophys Acta 2007, 1773(8): 1263-84.
5. Wan, P.T., Garnett, M.J., Roe, S.M. et al. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 2004, 116(6): 855-67.
6. V600E mutational status and sustained extracellular signal-regulated kinase/mitogen-activated protein kinase pathway suppression. Cancer Res 2009, 69(7): 3042-51.
7. Zhang, B.H., Guan, K.L. Activation of B-Raf kinase requires phosphorylation of the conserved residues Thr598 and Ser601. EMBO J 2000, 19(20): 5429-39.
8. Goydos, J.S., Mann, B., Kim, H.J. et al. Detection of B-RAF and N-RAS mutations in human melanoma. J Am Coll Surg 2005, 200(3): 362-70.
9. Libra, M., Malaponte, G., Navolanic, P.M. et al. Analysis of BRAF mutation in primary and metastatic melanoma. Cell Cycle 2005, 4(10): 1382-4.
10. Garnett, M.J., Marais, R. Guilty as charged: B-RAF is a human oncogene. Cancer Cell 2004, 6(4): 313-9.
11. Fransen, K., Klintenas, M., Osterstrom, A., Dimberg, J., Monstein, H.J., Soderkvist, P. Mutation analysis of the BRAF, ARAF and RAF-1 genes in human colorectal adenocarcinomas. Carcinogenesis 2004, 25(4): 527-33.
12. Davies, H., Bignell, G.R., Cox, C. et al. Mutations of the BRAF gene in human cancer. Nature 2002, 417(6892): 949-54.
13. Tsai, J., Lee, J.T., Wang, W. et al. Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity. Proc Natl Acad Sci U S A 2008, 105(8): 3041-6.
14. Sala, E., Mologni, L., Truffa, S., Gaetano, C., Bollag, G.E., Gambacorti-Passerini, C. BRAF silencing by short hairpin RNA or chemical blockade by PLX4032 leads to different responses in melanoma and thyroid carcinoma cells. Mol Cancer Res 2008, 6(5): 751-9.
15. Bollag, G., Hirth, P., Tsai, J. et al. Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature 2010, 467(7315): 596-9.
16. Joseph, E.W., Pratilas, C.A., Poulikakos, P.I. et al. The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner. Proc Natl Acad Sci U S A 2010, 107(33): 14903-8.
17. Yang, H., Higgins, B., Kolinsky, K. et al. RG7204 (PLX4032), a selective BRAFV600E inhibitor, displays potent antitumor activity in preclinical melanoma models. Cancer Res 2010, 70(13): 5518-27.
18. Halaban, R., Zhang, W., Bacchiocchi, A. et al. PLX4032, a selective BRAF(V600E) kinase inhibitor, activates the ERK pathway and enhances cell migration and proliferation of BRAF melanoma cells. Pigment Cell Melanoma Res 2010, 23(2): 190-200.
19. Rubinstein, J.C., Sznol, M., Pavlick, A.C. et al. Incidence of the V600K mutation among melanoma patients with BRAF mutations, and potential therapeutic response to the specific BRAF inhibitor PLX4032. J Transl Med 2010, 8 67.
20. Lee, J.T., Li, L., Brafford, P.A. et al. PLX4032, a potent inhibitor of the B-Raf V600E oncogene, selectively inhibits V600E-positive melanomas. Pigment Cell Melanoma Res 2010, 23(6): 820-7.
21. Tap, W.D., Gong, K.W., Dering, J. et al. Pharmacodynamic characterization of the efficacy signals due to selective BRAF inhibition with PLX4032 in malignant melanoma. Neoplasia 2010, 12(8): 637-49.
22. Salerno, P., De Falco, V., Tamburrino, A. et al. Cytostatic activity of adenosine triphosphate-competitive kinase inhibitors in BRAF mutant thyroid carcinoma cells. J Clin Endocrinol Metab 2010, 95(1): 450-5.
23. Sondergaard, J.N., Nazarian, R., Wang, Q. et al. Differential sensitivity of melanoma cell lines with BRAFV600E mutation to the specific Raf inhibitor PLX4032. J Transl Med 2010, 8: 39.
24. Xing, J., Liu, R., Xing, M., Trink, B. The BRAF(T1799A) mutation confers sensitivity of thyroid cancer cells to the BRAF(V600E) inhibitor PLX4032 (RG7204). Biochem Biophys Res Commun 2011, 404(4): 958-62.
25. Flaherty, K.T., Puzanov, I., Kim, K.B. et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 2010, 363(9): 809-19.
26. th Annu Meet Am Assoc Cancer Res (ASCO) (June 4-8, Chicago) 2010] 2010, 28(Suppl. 15S): Abst 8592.
27. th Annu Meet Am Assoc Cancer Res (ASCO) (June 4-8, Chicago) 2010] 2010, 28(Suppl. 15): Abst 3534.
28. th Annu Meet Am Assoc Cancer Res (ASCO) (June 4-8, Chicago) 2010] 2010, 28(Suppl. 15): Abst 8529.
29. Sosman, J., Kim, K., Schuchter, L. et al. An open-label, multicenter phase II study of continuous oral dosing of RG7204 (PLX4032) in previously treated patients with BRAF V600E mutation-positive metastatic melanoma. Pigment Cell Melanoma Res 2010, 23: 887.
30. Hatzivassiliou, G., Song, K., Yen, I. et al. RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Nature 2010, 464(7287): 431-5.
31. Heidorn, S.J., Milagre, C., Whittaker, S. et al. Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. Cell 2010, 140(2): 209-21.
32. Poulikakos, P.I., Zhang, C., Bollag, G., Shokat, K.M., Rosen, N. RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature 2010, 464(7287): 427-30.
33. Nazarian, R., Shi, H., Wang, Q. et al. Melanomas acquire resistance to BRAF(V600E) inhibition by RTK or N-RAS upregulation. Nature 2010, 468(7326): 973-7.
34. Villanueva, J., Vultur, A., Lee, J.T. et al. Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. Cancer Cell 2010, 18(6): 683-95.
35. Smalley, K.S., Haass, N.K., Brafford, P.A., Lioni, M., Flaherty, K.T., Herlyn, M. Multiple signaling pathways must be targeted to overcome drug resistance in cell lines derived from melanoma metastases. Mol Cancer Ther 2006, 5(5): 1136-44.
36. Lasithiotakis, K.G., Sinnberg, T.W., Schittek, B. et al. Combined inhibition of MAPK and mTOR signaling inhibits growth, induces cell death, and abrogates invasive growth of melanoma cells. J Invest Dermatol 2008, 128(8): 2013-23.
37. Johannessen, C.M., Boehm, J.S., Kim, S.Y. et al. COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature 2010, 468(7326): 968-72..